Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. [electronic resource]
Producer: 20200218Description: 463-472 p. digitalISSN:- 1944-7884
- Adult
- Aged
- Anti-Retroviral Agents -- administration & dosage
- Equivalence Trials as Topic
- Female
- HIV-1 -- drug effects
- Humans
- Lamivudine -- administration & dosage
- Male
- Middle Aged
- Protease Inhibitors -- therapeutic use
- Pyridones -- administration & dosage
- Quinolones -- therapeutic use
- Ritonavir -- therapeutic use
- Tenofovir -- administration & dosage
- Treatment Outcome
- Triazoles -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.